Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 1/Phase 2

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)

NCT ID: NCT04315324Sponsor: SWOG Cancer Research NetworkLast updated: 2025-08-15

Summary

This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.

Detailed description

PRIMARY OBJECTIVES: I. To assess the safety of AKR1C3-activated prodrug OBI-3424 (OBI-3424) and to determine the maximum tolerated dose (MTD) of OBI-3424 in this regimen for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LBL). (Phase I) II. To assess the response rate (complete remission \[CR\] or CR with incomplete count recovery \[CRi\]) of patients treated with OBI-3424 at the maximum tolerated dose (MTD) determined in the Phase I portion of the trial in this patient population. (Phase II) SECONDARY OBJECTIVES: I. To estimate the frequency and severity of toxicities of OBI-3424 in this patient population. II. To estimate event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS) in this patient population. TRANSLATIONAL MEDICINE OBJECTIVES: I. To estimate minimal/measurable residual disease (MRD) negativity (among patients who achieve CR or CRi). II. To assess AKR1C3 expression levels in this patient population. III. To evaluate associations between AKR1C3 expression and response to OBI-3424, achievement of MRD-negative remission, and relapse from remission. IV. To bank specimens for future research. OUTLINE: This is a phase I, dose-escalation study followed by a phase II study. Patients receive AKR1C3-activated prodrug OBI-3424 intravenously (IV) over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not achieved a partial remission (PR) by the 4th cycle of treatment are removed from the study (unless clinically benefiting in the opinion of the treating investigator). Patients undergo blood sample collection during screening and cerebrospinal fluid (CSF) sample collection on study. Patients also undergo bone marrow aspirate or core biopsy and may undergo computed tomography (CT) scan throughout the study. After completion of study treatment, patients are followed up every month for 1 year, every 2 months for 1 year, every 3 months for 1 year, and then every 6 months for up to 5 years from registration.

Arms & interventions

  • DrugAKR1C3-activated Prodrug AST-3424

    Given IV

  • ProcedureBiopsy Procedure

    Undergo biopsy

  • ProcedureBiospecimen Collection

    Undergo blood and CSF sample collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspirate

  • ProcedureComputed Tomography

    Undergo CT scan

Outcome measures

Primary

  • Maximum tolerated dose (MTD) (Phase I)

    The regimen will be considered safe and the MTD determined if the dose-limiting toxicity rate is \< 33%.

    Time frame: Up to 21 days

  • Response rate (complete remission [CR] or CR with incomplete count recovery [CRi]) (Phase II)

    Time frame: Up to 5 years

Secondary

  • Incidence of adverse events

    Time frame: Up to the time of relapse, assessed up to 5 years

  • Overall survival

    Time frame: From the day of registration on study until death from any cause with observations censored on the day of last contact for patients not known to have died, assessed up to 5 years

  • Event-free survival

    Time frame: From the date of initial registration on study until the first of the following events: death from any cause, relapse from remission (CR or CRi) or completion of protocol therapy without documentation of CR or CRi, assessed up to 5 years

  • Relapse-free survival

    Time frame: From the date the patient first achieves CR or CRi until relapse from CR/CRi or death from any cause, assessed up to 5 years

Eligibility criteria

Sex: AllAge: 12 Years and olderHealthy volunteers: No
Inclusion Criteria: * Patients must have a diagnosis of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) based on World Health Organization (WHO) classification. Patients with relapsed/refractory T-cell lymphoblastic lymphoma are eligible if lymphoblasts are \>= 5% in the bone marrow or in the peripheral blood by morphology or flow cytometry * Patients must have evidence of acute leukemia in their peripheral blood or bone marrow. Patients must have \>= 5% lymphoblasts in the peripheral blood or bone marrow within 14 days prior to registration. Patients with only extramedullary disease are not eligible * Patients ≥ 18 years of age must be refractory to or have relapsed following a standard induction chemotherapy. Patients \< 18 years of age must have relapsed or must be refractory after 2 or more chemotherapy cycles (example: induction and consolidation) * A standard chemotherapy induction regimen is defined as any program of treatment that includes: * Vincristine and corticosteroids plus at least one more chemotherapy agent * Cytarabine and anthracycline, or * High dose cytarabine (defined as at least 1 gr/m\^2 per individual dose unless adjustments were required for renal/liver function) * Patients must have no evidence of central nervous system disease within 28 days prior to registration based on cerebrospinal fluid (CSF) studies. Patients with clinical signs or symptoms consistent with central nervous system (CNS) involvement must have a lumbar puncture which is negative for CNS involvement; the lumbar puncture must be completed within 28 days prior to registration. Patients with CNS1 or CNS2 are eligible; however patients with CNS3 are not eligible * Note that the patients may receive intrathecal chemotherapy with the initial lumbar puncture. This may count as the first dose of intrathecal therapy required as part of the study * Prior nelarabine therapy is not required. In addition, for patients ≥ 18 years of age who received nelarabine during initial induction or post-remission treatment are eligible only if the physician does not feel they would benefit from other, multi-agent chemotherapy * Patients must not have had chemotherapy or investigational agents within 14 days prior to registration except for corticosteroids, oral 6-mercaptopurine, oral methotrexate, vincristine, intrathecal chemotherapy, or hydroxyurea. For participants who have received radiation therapy, at least 7 days must have elapsed from the end of radiation prior to registration and participants must not currently be experiencing toxicities from radiation therapy * Patients must not have undergone allogeneic hematopoietic transplant within 90 days prior to registration * Patients must have no evidence of active \>= grade 2 acute graft versus host disease (GVHD) or moderate or severe limited chronic GVHD. Patients must have no history of extensive GVHD of any severity within 90 days prior to registration. Patients who are post-transplant must be off calcineurin inhibitors for at least 21 days to be eligible. Extensive GVHD is defined as 1) generalized skin involvement or 2) localized skin involvement and/or hepatic dysfunction plus liver histology or cirrhosis or involvement of eye or minor salivary organ or oral mucosa or any other target organ * Patients must be \>= 12 years of age * Patients ≥ 16 years of age must have a Zubrod Performance Status of 0-3. Patients \< 16 years of age must have a Lansky score of ≥ 50 * Patients must not have systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment) within 14 days prior to registration * Patients ≥ 18 years of age must have creatinine clearance \> 30 mL/min within 14 days prior to registration according to the Cockcroft Gault equation * Patients 12-17 years of age must have adequate renal function within 14 days prior to registration defined as serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN) according to age or a calculated estimated glomerular filtration rate (eGFR) (based on Schwartz formula) or radioisotope glomerular filtration rate (GFR) ≥ 50ml/min/1.73 m\^2 * Patients must have direct bilirubin =\< 1.5 x institutional upper limit of normal (ULN) within 14 days prior to registration * Patients must have alanine aminotransferase (ALT) =\< 3.0 x institutional upper limit of normal (ULN) or =\< 5.0 x ULN (if thought to be related to leukemic involvement) within 14 days prior to registration * Prothrombin time (PT)/partial thromboplastin time (PTT)/ fibrinogen (as clinically indicated for example but not limited to history of bleeding or active bleeding, concern for disseminated intravascular coagulation) (within 14 days prior to registration to obtain baseline measurements) * From metabolic panel (comprehensive or basic): sodium, potassium, chloride, carbon dioxide (CO2), and blood urea nitrogen (BUN) (within 14 days prior to registration to obtain baseline measurements) * Patients must be able to safely discontinue use of strong inhibitors/inducers of CYP3A4 or PgP-g-p and must be able to safely discontinue use of naproxen for 48 hours before and after each dose of OBI-3424 * Patients with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test within 6 months prior to registration. (HIV viral load testing is required only for patients with known HIV infection). Patients must not be receiving antiviral therapies that are known strong inhibitors or inducers of CYP3A4 * Patients with evidence of chronic hepatitis B virus (HBV) infection may be eligible provided that they have an undetectable HBV viral load within 28 days prior to registration. Patients may be currently receiving HBV treatment. (HBV viral load testing is required only for patients with known HBV infection). Patients must not be receiving antiviral therapies that are known strong inhibitors or inducers of CYP3A4 * Patients with known history of hepatitis C virus (HCV) infection may be eligible provided that they have an undetectable HCV viral load within in 28 days prior to registration. Patients may be currently receiving treatment. (HCV viral load testing is required only for patients with known HCV infection). Patients must not be receiving antiviral therapies that are known strong inhibitors or inducers of CYP3A4 * Patients must not have a known history of prolonged QT interval by Fridericia (QTcF) (interval \> 450 msec for males; \> 470 msec for females). Patients that had transient prolongation of QTc secondary to medications or electrolyte abnormalities are not excluded if the QTc normalized and remain within acceptable QTcF range (interval \> 450 msec for males; \> 470 msec for females). Additionally, suspected medications should be no longer required or used, and electrolyte abnormalities must have normalized * Patients must not be pregnant or nursing due to the teratogenic potential of the drug used on this study. Females of reproductive potential must have a negative serum pregnancy test within 14 days prior to registration. Women/men of reproductive potential must have agreed to use an effective contraceptive method during and up to 6 months after treatment. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures * Patients must not have other active malignancies for which they have received treatments within 6 months prior to registration excluding localized malignancies that do not require systemic treatment * Patients must agree to have bone marrow and blood specimens submitted for MRD testing * Patients must be offered the opportunity to participate in specimen banking. With patient consent, residuals from specimens submitted will be retained and banked for future research * Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with fedral, local, institutional and Central Institutional Review Board (CIRB) guidelines unless they are unable to provide consent based on age (\< 18 years) or based on impaired decision-making capabilities. For patients \< 18 years of age or with impaired decision making capabilities, parents or other legally authorized representatives must sign and give informed consent on behalf of study participants in accordance with applicable federal, local, institutional and CIRB regulations * As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * This trial will use a slot reservation system to enroll the Phase I portion of the study. Patients planning to enroll at this phase of the study must first have a slot reserved in advance of the registration. All site staff will use OPEN to create a slot reservation

Study locations (163)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233

Active Not Recruiting

Kingman Regional Medical Center

Kingman, Arizona, 86401

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Arkansas Children's Hospital

Little Rock, Arkansas, 72202-3591

Recruiting
Site Public Contact · Contact
501-364-7373
David L. Becton · Principal Investigator

PCR Oncology

Arroyo Grande, California, 93420

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

City of Hope Comprehensive Cancer Center

Duarte, California, 91010

Recruiting
Site Public Contact · Contact
800-826-4673becomingapatient@coh.org
Ibrahim Aldoss · Principal Investigator

Loma Linda University Medical Center

Loma Linda, California, 92354

Recruiting
Site Public Contact · Contact
909-558-4050
Albert Kheradpour · Principal Investigator

Children's Hospital of Orange County

Orange, California, 92868

Recruiting
Site Public Contact · Contact
714-509-8646oncresearch@choc.org
Elyssa M. Rubin · Principal Investigator

Children's Hospital Colorado

Aurora, Colorado, 80045

Recruiting
Site Public Contact · Contact
303-764-5056josh.b.gordon@nsmtp.kp.org
Kelly E. Faulk · Principal Investigator

Alfred I duPont Hospital for Children

Wilmington, Delaware, 19803

Recruiting
Site Public Contact · Contact
302-651-5572Allison.bruce@nemours.org
Emi H. Caywood · Principal Investigator

Golisano Children's Hospital of Southwest Florida

Fort Myers, Florida, 33908

Recruiting
Site Public Contact · Contact
239-343-5333molly.arnstrom@leehealth.org
Emad K. Salman · Principal Investigator

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

Hollywood, Florida, 33021

Recruiting
Site Public Contact · Contact
954-265-1847OHR@mhs.net
Iftikhar Hanif · Principal Investigator

Johns Hopkins All Children's Hospital

St. Petersburg, Florida, 33701

Recruiting
Site Public Contact · Contact
727-767-4784Ashley.Repp@jhmi.edu
Jennifer B. Dean · Principal Investigator

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322

Recruiting
Site Public Contact · Contact
404-778-1868
Nikolaos Papadantonakis · Principal Investigator

Children's Healthcare of Atlanta - Arthur M Blank Hospital

Atlanta, Georgia, 30329

Recruiting
Site Public Contact · Contact
404-785-0232Olivia.Floyd@choa.org
Ryan J. Summers · Principal Investigator

Augusta University Medical Center

Augusta, Georgia, 30912

Recruiting
Site Public Contact · Contact
706-721-2388ga_cares@augusta.edu
Colleen H. McDonough · Principal Investigator

Loyola Center for Health at Burr Ridge

Burr Ridge, Illinois, 60527

Active Not Recruiting

Lurie Children's Hospital-Chicago

Chicago, Illinois, 60611

Recruiting
Site Public Contact · Contact
773-880-4562
Jenna Rossoff · Principal Investigator

Northwestern University

Chicago, Illinois, 60611

Recruiting
Site Public Contact · Contact
312-695-1301cancer@northwestern.edu
Shira N. Dinner · Principal Investigator

University of Illinois

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-355-3046
John G. Quigley · Principal Investigator

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Active Not Recruiting

Loyola Medicine Homer Glen

Homer Glen, Illinois, 60491

Active Not Recruiting

Northwestern Medicine Lake Forest Hospital

Lake Forest, Illinois, 60045

Active Not Recruiting

Loyola University Medical Center

Maywood, Illinois, 60153

Active Not Recruiting

Marjorie Weinberg Cancer Center at Loyola-Gottlieb

Melrose Park, Illinois, 60160

Active Not Recruiting

UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451

Active Not Recruiting

University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462

Active Not Recruiting

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Gregory P. Brandt · Principal Investigator

Mary Greeley Medical Center

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Ames

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-239-4734ksoder@mcfarlandclinic.com
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Boone

Boone, Iowa, 50036

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Trinity Cancer Center

Fort Dodge, Iowa, 50501

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Jefferson

Jefferson, Iowa, 50129

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Marshalltown

Marshalltown, Iowa, 50158

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

Norton Children's Hospital

Louisville, Kentucky, 40202

Recruiting
Site Public Contact · Contact
502-629-5500CancerResource@nortonhealthcare.org
Michael J. Ferguson · Principal Investigator

LSU Health Baton Rouge-North Clinic

Baton Rouge, Louisiana, 70805

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Nakhle S. Saba · Principal Investigator

Our Lady of the Lake Physician Group

Baton Rouge, Louisiana, 70808

Recruiting
Site Public Contact · Contact
225-765-7659research@ololrmc.com
Nakhle S. Saba · Principal Investigator

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287

Recruiting
Site Public Contact · Contact
410-955-8804jhcccro@jhmi.edu
Stacy L. Cooper · Principal Investigator

Bronson Battle Creek

Battle Creek, Michigan, 49017

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201

Active Not Recruiting

Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334

Active Not Recruiting

Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Grand Rapids, Michigan, 49503

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital

Grand Rapids, Michigan, 49503

Recruiting
Site Public Contact · Contact
616-267-1925crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Trinity Health Grand Rapids Hospital

Grand Rapids, Michigan, 49503

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Bronson Methodist Hospital

Kalamazoo, Michigan, 49007

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

West Michigan Cancer Center

Kalamazoo, Michigan, 49007

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Beacon Kalamazoo Cancer Center

Kalamazoo, Michigan, 49009

Recruiting
Site Public Contact · Contact
574-647-7370
Kathleen Y. Butler · Principal Investigator

Beacon Kalamazoo

Kalamazoo, Michigan, 49048

Recruiting
Site Public Contact · Contact
574-647-7370
Kathleen Y. Butler · Principal Investigator

Trinity Health Muskegon Hospital

Muskegon, Michigan, 49444

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Corewell Health Lakeland Hospitals - Niles Hospital

Niles, Michigan, 49120

Recruiting
Site Public Contact · Contact
616-391-1230
Kathleen Y. Butler · Principal Investigator

Cancer and Hematology Centers of Western Michigan - Norton Shores

Norton Shores, Michigan, 49444

Recruiting
Site Public Contact · Contact
616-391-1230connie.szczepanek@crcwm.org
Kathleen Y. Butler · Principal Investigator

Corewell Health Reed City Hospital

Reed City, Michigan, 49677

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

Saint Joseph, Michigan, 49085

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Corewell Health Lakeland Hospitals - Saint Joseph Hospital

Saint Joseph, Michigan, 49085

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Munson Medical Center

Traverse City, Michigan, 49684

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

University of Michigan Health - West

Wyoming, Michigan, 49519

Recruiting
Site Public Contact · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen Y. Butler · Principal Investigator

Fairview Ridges Hospital

Burnsville, Minnesota, 55337

Active Not Recruiting

Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337

Active Not Recruiting

Cambridge Medical Center

Cambridge, Minnesota, 55008

Active Not Recruiting

Mercy Hospital

Coon Rapids, Minnesota, 55433

Active Not Recruiting

Fairview Southdale Hospital

Edina, Minnesota, 55435

Active Not Recruiting

Unity Hospital

Fridley, Minnesota, 55432

Active Not Recruiting

Fairview Clinics and Surgery Center Maple Grove

Maple Grove, Minnesota, 55369

Active Not Recruiting

Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, 55109

Active Not Recruiting

Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109

Active Not Recruiting

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Active Not Recruiting

Hennepin County Medical Center

Minneapolis, Minnesota, 55415

Active Not Recruiting

Health Partners Inc

Minneapolis, Minnesota, 55454

Active Not Recruiting

University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, 55455

Recruiting
Site Public Contact · Contact
612-624-2620
Peter M. Gordon · Principal Investigator

Monticello Cancer Center

Monticello, Minnesota, 55362

Active Not Recruiting

New Ulm Medical Center

New Ulm, Minnesota, 56073

Active Not Recruiting

Fairview Northland Medical Center

Princeton, Minnesota, 55371

Active Not Recruiting

North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422

Active Not Recruiting

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Active Not Recruiting

Regions Hospital

Saint Paul, Minnesota, 55101

Active Not Recruiting

United Hospital

Saint Paul, Minnesota, 55102

Active Not Recruiting

Saint Francis Regional Medical Center

Shakopee, Minnesota, 55379

Active Not Recruiting

Lakeview Hospital

Stillwater, Minnesota, 55082

Active Not Recruiting

Ridgeview Medical Center

Waconia, Minnesota, 55387

Active Not Recruiting

Rice Memorial Hospital

Willmar, Minnesota, 56201

Active Not Recruiting

Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125

Active Not Recruiting

Fairview Lakes Medical Center

Wyoming, Minnesota, 55092

Active Not Recruiting

Children's Mercy Hospitals and Clinics

Kansas City, Missouri, 64108

Recruiting
Site Public Contact · Contact
816-302-6808rryan@cmh.edu
Kevin F. Ginn · Principal Investigator

Children's Hospital and Medical Center of Omaha

Omaha, Nebraska, 68114

Recruiting
Site Public Contact · Contact
402-955-3949
Jill C. Beck · Principal Investigator

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Recruiting
Site Public Contact · Contact
402-559-6941unmcrsa@unmc.edu
Jill C. Beck · Principal Investigator

Carson Tahoe Regional Medical Center

Carson City, Nevada, 89703

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Cancer and Blood Specialists-Henderson

Henderson, Nevada, 89052

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Comprehensive Cancer Centers of Nevada - Henderson

Henderson, Nevada, 89052

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Comprehensive Cancer Centers of Nevada-Horizon Ridge

Henderson, Nevada, 89052

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Las Vegas Cancer Center-Henderson

Henderson, Nevada, 89052

Suspended

OptumCare Cancer Care at Seven Hills

Henderson, Nevada, 89052

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Comprehensive Cancer Centers of Nevada-Southeast Henderson

Henderson, Nevada, 89074

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

GenesisCare USA - Henderson

Henderson, Nevada, 89074

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Las Vegas Urology - Green Valley

Henderson, Nevada, 89074

Recruiting
Site Public Contact · Contact
research@sncrf.org
John A. Ellerton · Principal Investigator

Las Vegas Urology - Pebble

Henderson, Nevada, 89074

Recruiting
Site Public Contact · Contact
research@sncrf.org
John A. Ellerton · Principal Investigator

Urology Specialists of Nevada - Green Valley

Henderson, Nevada, 89074

Recruiting
Site Public Contact · Contact
research@sncrf.org
John A. Ellerton · Principal Investigator

Las Vegas Urology - Pecos

Las Vegas, Nevada, 89074

Recruiting
Site Public Contact · Contact
research@sncrf.org
John A. Ellerton · Principal Investigator

Desert West Surgery

Las Vegas, Nevada, 89102

Suspended

OptumCare Cancer Care at Charleston

Las Vegas, Nevada, 89102

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

University Medical Center of Southern Nevada

Las Vegas, Nevada, 89102

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Hope Cancer Care of Nevada

Las Vegas, Nevada, 89103

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Radiation Oncology Centers of Nevada Central

Las Vegas, Nevada, 89106

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Urology Specialists of Nevada - Central

Las Vegas, Nevada, 89106

Recruiting
Site Public Contact · Contact
research@sncrf.org
John A. Ellerton · Principal Investigator

GenesisCare USA - Las Vegas

Las Vegas, Nevada, 89109

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway

Las Vegas, Nevada, 89109

Suspended

Sunrise Hospital and Medical Center

Las Vegas, Nevada, 89109

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-San Martin

Las Vegas, Nevada, 89113

Suspended

Las Vegas Prostate Cancer Center

Las Vegas, Nevada, 89113

Recruiting
Site Public Contact · Contact
research@sncrf.org
John A. Ellerton · Principal Investigator

Las Vegas Urology - Sunset

Las Vegas, Nevada, 89113

Recruiting
Site Public Contact · Contact
research@sncrf.org
John A. Ellerton · Principal Investigator

Urology Specialists of Nevada - Southwest

Las Vegas, Nevada, 89113

Recruiting
Site Public Contact · Contact
research@sncrf.org
John A. Ellerton · Principal Investigator

Radiation Oncology Centers of Nevada Southeast

Las Vegas, Nevada, 89119

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Ann M Wierman MD LTD

Las Vegas, Nevada, 89128

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Comprehensive Cancer Centers of Nevada - Northwest

Las Vegas, Nevada, 89128

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

GenesisCare USA - Vegas Tenaya

Las Vegas, Nevada, 89128

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-Tenaya

Las Vegas, Nevada, 89128

Suspended

Las Vegas Urology - Cathedral Rock

Las Vegas, Nevada, 89128

Recruiting
Site Public Contact · Contact
research@sncrf.org
John A. Ellerton · Principal Investigator

Las Vegas Urology - Smoke Ranch

Las Vegas, Nevada, 89128

Recruiting
Site Public Contact · Contact
research@smcrf.org
John A. Ellerton · Principal Investigator

OptumCare Cancer Care at MountainView

Las Vegas, Nevada, 89128

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Urology Specialists of Nevada - Northwest

Las Vegas, Nevada, 89128

Recruiting
Site Public Contact · Contact
research@sncrf.org
John A. Ellerton · Principal Investigator

Alliance for Childhood Diseases/Cure 4 the Kids Foundation

Las Vegas, Nevada, 89135

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Comprehensive Cancer Centers of Nevada - Town Center

Las Vegas, Nevada, 89144

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Comprehensive Cancer Centers of Nevada-Summerlin

Las Vegas, Nevada, 89144

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Summerlin Hospital Medical Center

Las Vegas, Nevada, 89144

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Las Vegas Cancer Center-Medical Center

Las Vegas, Nevada, 89148-2405

Suspended

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89148

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

GenesisCare USA - Fort Apache

Las Vegas, Nevada, 89148

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

OptumCare Cancer Care at Fort Apache

Las Vegas, Nevada, 89148

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills

Las Vegas, Nevada, 89149

Suspended

Comprehensive Cancer Centers of Nevada - Central Valley

Las Vegas, Nevada, 89169

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

University Cancer Center

Las Vegas, Nevada, 89169

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Hope Cancer Care of Nevada-Pahrump

Pahrump, Nevada, 89048

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Renown Regional Medical Center

Reno, Nevada, 89502

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Saint Mary's Regional Medical Center

Reno, Nevada, 89503

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Radiation Oncology Associates

Reno, Nevada, 89509

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106

Recruiting
Site Public Contact · Contact
505-925-0348HSC-ClinicalTrialInfo@salud.unm.edu
Charles Foucar · Principal Investigator

Roswell Park Cancer Institute

Buffalo, New York, 14263

Active Not Recruiting

University of Rochester

Rochester, New York, 14642

Recruiting
Site Public Contact · Contact
585-275-5830
Paul M. Barr · Principal Investigator

Duke University Medical Center

Durham, North Carolina, 27710

Recruiting
Site Public Contact · Contact
888-275-3853
Harry P. Erba · Principal Investigator

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219

Recruiting
Site Public Contact · Contact
513-584-7698cancer@uchealth.com
Emily K. Curran · Principal Investigator

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229

Recruiting
Site Public Contact · Contact
513-636-2799cancer@cchmc.org
Erin H. Breese · Principal Investigator

Cleveland Clinic Foundation

Cleveland, Ohio, 44195

Recruiting
Site Public Contact · Contact
866-223-8100TaussigResearch@ccf.org
Anjali S. Advani · Principal Investigator

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069

Suspended

Oregon Health and Science University

Portland, Oregon, 97239

Active Not Recruiting

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104

Recruiting
Site Public Contact · Contact
267-425-5544CancerTrials@email.chop.edu
Susan R. Rheingold · Principal Investigator

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, 15224

Recruiting
Site Public Contact · Contact
412-692-8570jean.tersak@chp.edu
Colleen Mathews · Principal Investigator

Rhode Island Hospital

Providence, Rhode Island, 02903

Recruiting
Site Public Contact · Contact
401-444-1488
Bradley DeNardo · Principal Investigator

Prisma Health Richland Hospital

Columbia, South Carolina, 29203

Recruiting
Site Public Contact · Contact
864-522-4317Kim.Williams3@prismahealth.org
Stuart L. Cramer · Principal Investigator

The Children's Hospital at TriStar Centennial

Nashville, Tennessee, 37203

Recruiting
Site Public Contact · Contact
615-342-1919
Clinton M. Carroll · Principal Investigator

Dell Children's Medical Center of Central Texas

Austin, Texas, 78723

Recruiting
Site Public Contact · Contact
512-628-1902TXAUS-DL-SFCHemonc.research@ascension.org
Shannon M. Cohn · Principal Investigator

El Paso Children's Hospital

El Paso, Texas, 79905

Recruiting
Site Public Contact · Contact
915-298-5444ranjan.bista@ttuhsc.edu
Benjamin Carcamo · Principal Investigator

Methodist Children's Hospital of South Texas

San Antonio, Texas, 78229

Recruiting
Site Public Contact · Contact
210-575-6240Vinod.GidvaniDiaz@hcahealthcare.com
Jose M. Esquilin · Principal Investigator

University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229

Recruiting
Site Public Contact · Contact
210-450-3800phoresearchoffice@uthscsa.edu
Anne-Marie R. Langevin · Principal Investigator

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112

Recruiting
Site Public Contact · Contact
888-424-2100cancerinfo@hci.utah.edu
Paul J. Shami · Principal Investigator

University of Virginia Cancer Center

Charlottesville, Virginia, 22908

Recruiting
Site Public Contact · Contact
434-243-6303uvacancertrials@hscmail.mcc.virginia.edu
Brian C. Belyea · Principal Investigator

Children's Hospital of The King's Daughters

Norfolk, Virginia, 23507

Recruiting
Site Public Contact · Contact
757-668-7243CCBDCresearch@chkd.org
Melissa S. Mark · Principal Investigator

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298

Recruiting
Site Public Contact · Contact
804-628-6430CTOclinops@vcu.edu
Thuy Ho · Principal Investigator

Overlake Medical Center

Bellevue, Washington, 98004

Suspended

Valley Medical Center

Renton, Washington, 98055

Recruiting
Site Public Contact · Contact
425-228-3440research@valleymed.org
John A. Ellerton · Principal Investigator

Fred Hutchinson Cancer Center

Seattle, Washington, 98109

Recruiting
Site Public Contact · Contact
800-804-8824
Ryan D. Cassaday · Principal Investigator

University of Washington Medical Center - Montlake

Seattle, Washington, 98195

Recruiting
Site Public Contact · Contact
800-804-8824
Ryan D. Cassaday · Principal Investigator

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

Yakima, Washington, 98902

Recruiting
Site Public Contact · Contact
509-574-3535Memorial-ClinicalTrials@yvmh.org
John A. Ellerton · Principal Investigator

West Virginia University Healthcare

Morgantown, West Virginia, 26506

Recruiting
Site Public Contact · Contact
304-293-7374cancertrialsinfo@hsc.wvu.edu
Lauren W. Veltri · Principal Investigator

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601

Active Not Recruiting

Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017

Active Not Recruiting